LU91271I2 - Natalizumab et ses dérivés pharmaceutiquement acceptables (TYSABRI) - Google Patents

Natalizumab et ses dérivés pharmaceutiquement acceptables (TYSABRI)

Info

Publication number
LU91271I2
LU91271I2 LU91271C LU91271C LU91271I2 LU 91271 I2 LU91271 I2 LU 91271I2 LU 91271 C LU91271 C LU 91271C LU 91271 C LU91271 C LU 91271C LU 91271 I2 LU91271 I2 LU 91271I2
Authority
LU
Luxembourg
Prior art keywords
tysabri
natalizumab
pharmaceutically acceptable
acceptable derivatives
treatment
Prior art date
Application number
LU91271C
Other languages
English (en)
French (fr)
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Publication of LU91271I2 publication Critical patent/LU91271I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LU91271C 1994-01-25 2006-08-02 Natalizumab et ses dérivés pharmaceutiquement acceptables (TYSABRI) LU91271I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18626994A 1994-01-25 1994-01-25
PCT/US1995/001219 WO1995019790A1 (en) 1994-01-25 1995-01-25 Humanized antibodies against leukocyte adhesion molecule vla-4

Publications (1)

Publication Number Publication Date
LU91271I2 true LU91271I2 (fr) 2006-10-02

Family

ID=22684288

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91271C LU91271I2 (fr) 1994-01-25 2006-08-02 Natalizumab et ses dérivés pharmaceutiquement acceptables (TYSABRI)

Country Status (21)

Country Link
EP (2) EP1759709B1 (OSRAM)
JP (5) JP4115517B2 (OSRAM)
KR (1) KR100367948B1 (OSRAM)
CN (1) CN1211123C (OSRAM)
AT (1) ATE333895T1 (OSRAM)
AU (1) AU703152B2 (OSRAM)
CA (1) CA2182013C (OSRAM)
DE (2) DE122006000043I1 (OSRAM)
DK (2) DK1759709T3 (OSRAM)
ES (2) ES2424292T3 (OSRAM)
FI (1) FI117509B (OSRAM)
FR (1) FR06C0024I2 (OSRAM)
HU (1) HU220799B1 (OSRAM)
LU (1) LU91271I2 (OSRAM)
MX (1) MX9602971A (OSRAM)
NL (1) NL300238I2 (OSRAM)
NO (3) NO319867B1 (OSRAM)
NZ (1) NZ279730A (OSRAM)
PL (1) PL181827B1 (OSRAM)
PT (1) PT804237E (OSRAM)
WO (1) WO1995019790A1 (OSRAM)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307025B1 (en) 1989-04-28 2001-10-23 Biogen, Inc. VCAM fusion proteins and DNA coding therefor
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
DE69419721T2 (de) 1993-01-12 2000-04-27 Biogen, Inc. Rekombinante anti-vla4 antikörpermoleküle
NZ262615A (en) * 1993-02-09 1996-02-27 Biogen Inc Treating insulin dependent diabetes (type i) with anti vla4 (very late antigen) antibodies
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US7750137B2 (en) 1995-09-01 2010-07-06 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
AU7348798A (en) * 1997-05-09 1998-12-08 John P. Robarts Research Institute, The Method for dislodging infiltrated leukocytes from a tissue
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
DE69940206D1 (de) * 1998-09-14 2009-02-12 Univ Texas Verfahren zur behandlung von multiplem myelom und von myelom- induzierter knochenresorption mit antagonisten der integrin-/rezeptorbindung
DE60020955T2 (de) * 1999-04-22 2006-05-11 Biogen Idec Ma Inc., Cambridge Verfahren zur behandlung einer fibrose unter verwendung eines antagonisten der integrin alpha-4 untereinheit
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
EE200100651A (et) 1999-06-01 2003-02-17 Biogen, Inc. VLA-1 blokeeriv monoklonaalne antikeha ja tema kasutamine põletiku raviks
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
EP2140881B1 (en) * 1999-12-16 2013-04-17 Biogen Idec MA Inc. Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
MXPA03009390A (es) 2001-04-13 2004-01-29 Biogen Inc Anticuerpos para integrina vla-1.
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
DK2336184T3 (en) * 2002-02-25 2015-02-16 Biogen Idec Inc Administration of agents for the treatment of inflammation.
EP1499352A4 (en) * 2002-04-12 2006-10-11 Medimmune Inc ANTI-INTERLEUKIN-9 RECOMBINANT ANTIBODIES
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
AR040778A1 (es) * 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
EP1572748B1 (en) * 2002-12-17 2010-06-23 MERCK PATENT GmbH Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
CU23403A1 (es) * 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
EP2803667A1 (en) 2003-12-22 2014-11-19 Ajinomoto Co., Inc. Phenylalanine derivatives
WO2006055871A2 (en) * 2004-11-19 2006-05-26 Biogen Idec Ma Inc. Treatment for multiple sclerosis
JP2009515552A (ja) * 2005-11-17 2009-04-16 ミレニアム・ファーマシューティカルズ・インコーポレイテッド α４β７インテグリン反応性ヒト化免疫グロブリン
PL2034830T3 (pl) 2006-05-25 2015-04-30 Biogen Ma Inc Przeciwciało anty-VLA-1 do leczenia udaru
CA2714335A1 (en) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
MX2009013593A (es) * 2007-06-14 2010-01-20 Biogen Idec Inc Formulaciones de anticuerpos.
ES2466020T3 (es) 2007-12-13 2014-06-09 Tokuyama Corporation Composición fotocrómica curable
CA2721093A1 (en) 2008-04-11 2009-10-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
CN103382222B (zh) 2009-03-20 2016-12-28 安姆根有限公司 α-4-β-7异二聚体特异性拮抗剂抗体
US20120258093A1 (en) 2009-08-20 2012-10-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
PT2558499T (pt) 2010-04-16 2017-07-14 Biogen Ma Inc Anticorpos anti-vla-4
US10040855B2 (en) 2011-05-02 2018-08-07 Millennium Pharmaceuticals, Inc. Formulation for anti-α4β7 antibody
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
CN104271122A (zh) 2012-02-16 2015-01-07 桑塔鲁斯股份有限公司 抗vla1(cd49a)抗体药物组合物
US20190225694A1 (en) 2016-06-28 2019-07-25 Zaklady Farmaceutyczne Polpharma Sa Recombinant production of monoclonal antibodies
US20190374639A1 (en) 2016-11-21 2019-12-12 Polpharma Biologics S.A. Aqueous pharmaceutical formulations
CN118955707A (zh) * 2017-02-17 2024-11-15 赛诺菲 对肌营养不良蛋白聚糖和层粘连蛋白-2具有特异性的多特异性结合分子
WO2018224673A1 (en) 2017-06-08 2018-12-13 Zaklady Farmaceutyczne Polpharma S.A. Improved methods of cell culture
CN112867394B9 (zh) 2018-06-04 2024-12-06 马萨诸塞州渤健公司 具有降低的效应功能的抗vla-4抗体
WO2022162164A1 (en) 2021-01-29 2022-08-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
IL113261A (en) * 1989-09-01 1996-10-16 Hutchinson Fred Cancer Res Inhibition by peptides of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction and pharmaceutical compositions containing said peptides
WO1993015764A1 (en) * 1992-02-12 1993-08-19 Biogen, Inc. Treatment for inflammatory bowel disease
DE69419721T2 (de) * 1993-01-12 2000-04-27 Biogen, Inc. Rekombinante anti-vla4 antikörpermoleküle
AUPP647298A0 (en) 1998-10-13 1998-11-05 Keystone Retaining Wall Systems, Inc. Retaining wall block

Also Published As

Publication number Publication date
FI962958A0 (fi) 1996-07-24
AU1696095A (en) 1995-08-08
EP1759709A1 (en) 2007-03-07
JPH09508272A (ja) 1997-08-26
NO2017040I1 (no) 2017-08-01
DK0804237T3 (da) 2006-10-16
JP2006045237A (ja) 2006-02-16
AU703152B2 (en) 1999-03-18
DE69535133D1 (de) 2006-09-07
NO2006008I1 (no) 2006-08-07
FI117509B (fi) 2006-11-15
JP2009235078A (ja) 2009-10-15
EP0804237A1 (en) 1997-11-05
PL181827B1 (pl) 2001-09-28
NO319867B1 (no) 2005-09-26
FR06C0024I1 (OSRAM) 2006-10-13
ES2270425T3 (es) 2007-04-01
NO2006008I2 (no) 2009-06-15
PL315634A1 (en) 1996-11-25
CA2182013C (en) 2007-07-17
KR100367948B1 (ko) 2003-07-12
NL300238I2 (nl) 2007-05-01
CN1140413A (zh) 1997-01-15
MX9602971A (es) 1998-01-31
JP2013165718A (ja) 2013-08-29
DK1759709T3 (da) 2013-06-10
PT804237E (pt) 2006-10-31
NO963097D0 (no) 1996-07-24
CN1211123C (zh) 2005-07-20
JP2013173738A (ja) 2013-09-05
DE69535133T2 (de) 2008-08-21
EP0804237B8 (en) 2006-11-08
HUT75129A (en) 1997-04-28
NO963097L (no) 1996-09-24
CA2182013A1 (en) 1995-07-27
FI962958L (fi) 1996-09-24
WO1995019790A1 (en) 1995-07-27
EP0804237A4 (en) 2003-04-16
NZ279730A (en) 1998-04-27
EP1759709B1 (en) 2013-02-27
NL300238I1 (OSRAM) 2006-10-02
ES2424292T3 (es) 2013-09-30
FR06C0024I2 (fr) 2009-01-02
EP0804237B1 (en) 2006-07-26
HU9602019D0 (en) 1996-09-30
NO2017040I2 (no) 2018-08-28
JP5487382B2 (ja) 2014-05-07
DE122006000043I1 (de) 2007-02-15
HU220799B1 (hu) 2002-05-28
JP4115517B2 (ja) 2008-07-09
ATE333895T1 (de) 2006-08-15
KR970700513A (ko) 1997-02-12

Similar Documents

Publication Publication Date Title
LU91271I2 (fr) Natalizumab et ses dérivés pharmaceutiquement acceptables (TYSABRI)
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
LU92912I2 (fr) Mépolizumab et ses dérivés pharmaceutiquement acceptables (nucala)
ES2191292T3 (es) Compuestos antivirales poliaromaticos.
UA48940C2 (uk) Рекомбінатні il4 антитіла, які використовуються для лікування il4-опосередкованих порушень
ATE148130T1 (de) Typ-iv-dipeptidyl-aminopeptidase-inhibitoren
MY154009A (en) Anti-alpha v beta 6 antibodies
PT723538E (pt) Compostos triciclicos de carbamato uteis para a ainibicao da funcao da proteina g e para o tratamento de doencas proliferativas
BR9807674A (pt) Inibidores bicìclicos da proteìna farnesil transferase
ATE256671T1 (de) 2-phenyl-substituierte 1-(n-phenylaminoalkyl)- piperazin-derivate
AP9200410A0 (en) Retroviral protease inhibitors.
DE69831409D1 (de) Chalcon-derivate mit antiproliferativer aktivität
ATE199321T1 (de) Anti idiotypische antikörper gegen gonococcen und diese verwendende verfahren und zusammensetzungen.
ATE212548T1 (de) Behandlung und prophylaxe von pankreatitis
DE69736180D1 (de) Behandlung von manischen erkrankungen
ATE247955T1 (de) Selenophen-antitumormittel
DK1152760T3 (da) Anvendelse af 4-aminopyridin til behandling af perifere neuropatier
DK0517787T3 (da) Fremgangsmåde til behandling af terapiresistent skizofreni med amperozide
FR2721314B1 (fr) Dérivés de pyrrolidine, leur préparation et les médicaments les contenant.
BR9611520A (pt) Composto hemo-reguladores.
MX9704739A (es) Monomeros de 3,3-(disustituido)ciclohexan-1-ona y compuestos relacionados.